Activity of rifampicin and linezolid combination in Mycobacterium tuberculosis.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Tuberculosis

• Publication date

  2017-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.tube.2017.02.004PMID 28454646
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Linezolid for XDR-TB--Final Study Outcomes.

  2015cited by this paper
• Multidrug resistant tuberculosis

  2015cited by this paper
• Global tuberculosis report (2014)

  2014cited by this paper
• Fast detection of drug interaction in Mycobacterium tuberculosis by a checkerboard resazurin method.

  2013cited by this paper
• In vitro activity of linezolid against clinical isolates of Mycobacterium tuberculosis, including multidrug-resistant and extensively drug-resistant strains from Beijing, China.

  2012cited by this paper
• Linezolid for treatment of chronic extensively drug-resistant tuberculosis.

  2012cited by this paper
• Efficacy and safety of linezolid in the treatment of extensively drug-resistant tuberculosis.

  2011cited by this paper
• Susceptibility of Clinical Mycobacterium tuberculosis Isolates to a Potentially Less Toxic Derivate of Linezolid, PNU-100480

  2011cited by this paper
• An investigation of the antimicrobial impact of drug combinations against Mycobacterium tuberculosis strains

  2011cited by this paper
• Global tuberculosis drug development pipeline: the need and the reality.

  2010cited by this paper
• Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis.

  2010cited by this paper
• Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis.

  2009cited by this paper
• In vitro activity of linezolid against Mycobacterium tuberculosis strains isoalted from Western Turkey.

  2009cited by this paper
• [Effect of linezolid in combination with isoniazid and rifampicin against multidrug resistant Mycobacterium tuberculosis clinical isolates].

  2009cited by this paper
• In Vitro Activities of Linezolid against Clinical Isolates of Mycobacterium tuberculosis Complex Isolated in Taiwan over 10 Years

  2008cited by this paper
• Proposal for Standardization of Optimized Mycobacterial Interspersed Repetitive Unit-Variable-Number Tandem Repeat Typing of Mycobacterium tuberculosis

  2006cited by this paper
• In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii.

  2005cited by this paper
• In Vitro Activity of Linezolid against Slowly Growing Nontuberculous Mycobacteria

  2003cited by this paper
• In Vitro Activities of Linezolid against Clinical Isolates of Mycobacterium tuberculosis That Are Susceptible or Resistant to First-Line Antituberculous Drugs

  2003cited by this paper
• Synergic activity of fluoroquinolones and linezolid against Mycobacterium tuberculosis.

  2003cited by this paper
• Resazurin Microtiter Assay Plate: Simple and Inexpensive Method for Detection of Drug Resistance in Mycobacterium tuberculosis

  2002cited by this paper
• Linezolid: The first of a new class of antimicrobial agents

  2002cited by this paper
• Activities of Linezolid against Rapidly Growing Mycobacteria

  2001cited by this paper
• Activities of Several Novel Oxazolidinones againstMycobacterium tuberculosis in a Murine Model

  1999cited by this paper
• Rapid detection and simultaneous strain differentiation of Mycobacterium tuberculosis complex bacteria by spoligotyping.

  1998cited by this paper
• Multidrug resistant tuberculosis.

  1998cited by this paper
• Antibiotics in laboratory medicine

  1987cited by this paper
• [Antimicrobial combinations].

  1972cited by this paper

• Cationizing Lugdunin through Trp3 Hydrophobic Fine-Tuning and Cationic Side Chain Engineering.

  2026cites this paper
• Assessing transporter-mediated rifampin-linezolid interaction using physiologically-based pharmacokinetic modelling.

  2026cites this paper
• Confronting Tuberculosis: A Synthetic Quinoline-Isonicotinic Acid Hydrazide Hybrid Compound as a Potent Lead Molecule Against Mycobacterium tuberculosis.

  2024cites this paper
• Nebulized, macrophage-targeted, Linezolid-loaded lipid carriers for intracellular treatment of tubercular infections – In vitro/in vivo study

  2024cites this paper
• In vitro activities of contezolid (MRX-I) against drug-sensitive and drug-resistant Mycobacterium tuberculosis

  2023cites this paper
• Pre-Clinical Tools for Predicting Drug Efficacy in Treatment of Tuberculosis

  2022cites this paper
• Effect of rifampicin combination-regimens against multi-drug resistant strains in North India

  2022cites this paper
• Compassionate Use of Contezolid for the Treatment of Tuberculous Pleurisy in a Patient with a Leadless Pacemaker

  2022cites this paper
• In Vitro and In Vivo Activity of Oxazolidinone Candidate OTB-658 against Mycobacterium tuberculosis

  2021cites this paper
• Transcriptome signature of cell viability predicts drug response and drug interaction for Tuberculosis

  2021cites this paper
• Transcriptome signature of cell viability predicts drug response and drug interaction in Mycobacterium tuberculosis

  2021cites this paper
• Role of linezolid combination therapy for serious infections: review of the current evidence

  2020cites this paper
• Pharmacodynamic Functions of Synthetic Derivatives for Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) and Mycobacterium tuberculosis

  2020cites this paper
• Inhalable linezolid loaded PLGA nanoparticles for treatment of tuberculosis: Design, development and in vitro evaluation

  2020cites this paper
• Minimum Bactericidal Concentration Techniques in Mycobacterium tuberculosis: A Systematic Review

  2020cites this paper
• Increased activity of linezolid in combination with rifampicin in a murine pneumonia model due to MRSA

  2018cites this paper
• Bedaquiline and linezolid MIC distributions and epidemiological cut-off values for Mycobacterium tuberculosis in the Latin American region

  2018cites this paper
• Combinatory activity of linezolid and levofloxacin with antituberculosis drugs in Mycobacterium tuberculosis.

  2018cites this paper
• Carvacrol activity & morphological changes in Mycobacterium tuberculosis.

  2018cites this paper